With the agreement, Hitachi High-Technologies will gain exclusive rights to market Nanosphere products in Japan. The two companies also plan to collaborate on assay and platform development.
Hitachi High-Tech general manager Kazuhiro Matsumura said that Nanosphere’s portfolio of molecular diagnostics tests fits well with Japan’s demand for rapid and accurate diagnostic tools to fight infections, enabling clinicians to target therapies potentially improving critical patient care and outcomes.
"Nanosphere’s portfolio of molecular diagnostics tests fits well with Japan’s demand for rapid and accurate diagnostic tools to fight infections, enabling clinicians to target therapies potentially improving critical patient care and outcomes," Matsumura added.